Steven Lichtman
Stock Analyst at Oppenheimer
(3.01)
# 1,460
Out of 5,090 analysts
71
Total ratings
41.18%
Success rate
13.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $20.92 | +5.16% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $304.49 | +19.87% | 7 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $97.52 | +28.18% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $65.49 | +55.75% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $94.28 | +43.19% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.68 | +111.27% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $80.73 | +36.26% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $101.36 | -7.26% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $12.63 | +414.65% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $17.27 | -36.31% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $13.47 | -10.91% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $83.43 | +4.28% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.46 | +666.87% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $364.02 | -20.88% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $108.51 | -3.23% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $25.38 | +491.02% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $81.40 | +4.42% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $20.92
Upside: +5.16%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $304.49
Upside: +19.87%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $97.52
Upside: +28.18%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $65.49
Upside: +55.75%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $94.28
Upside: +43.19%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.68
Upside: +111.27%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $80.73
Upside: +36.26%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $101.36
Upside: -7.26%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $12.63
Upside: +414.65%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $17.27
Upside: -36.31%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $13.47
Upside: -10.91%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $83.43
Upside: +4.28%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.46
Upside: +666.87%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $364.02
Upside: -20.88%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $108.51
Upside: -3.23%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $25.38
Upside: +491.02%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $81.40
Upside: +4.42%